Breaking News

Juncell Therapeutics Opens New TIL Manufacturing Facility

With a total area exceeding 16,000 square meters, the new facility houses the company's production, quality, data, and operation centers.

Author Image

By: Charlie Sternberg

Associate Editor

Shanghai Juncell Therapeutics Co. Ltd., a clinical-stage biotech focused on innovative IL-2-independent Tumor-Infiltrating Lymphocyte (TIL) therapies, has opened its new TIL manufacturing facility located at Anting International Medical Industry Park in Jiading District, Shanghai, China.   Juncell Therapeutics’ latest facility, with a total area exceeding 16,000 square meters, houses the company’s production, quality, data, and operation centers. This facility, with a designed prod...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters